Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 12;75(8):1485-1486.
doi: 10.1093/cid/ciac389.

Response to 'Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome'

Kevin R Viel  1
Affiliations
Editorial

Response to 'Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome'

Kevin R Viel. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Stock or stock options: K. R. V. owns 10 shares of CytoDyn (CYDY). Other financial or nonfinancial interests: K. R. V. signed agreement that expires 2 July 2022 with a university to explore 2 patents covering CCR5 inhibition for indications not being pursued by CYDY (the patents expire in December 2024 and do not include a molecule). The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed

Comment in

  • Reply to Viel.
    Recknor C, Hansen SG, Gaylis NB, Tiwary M, Sacha JB, Yang OO. Recknor C, et al. Clin Infect Dis. 2022 Oct 12;75(8):1486-1487. doi: 10.1093/cid/ciac390. Clin Infect Dis. 2022. PMID: 35819204 No abstract available.

Comment on

References

    1. Gaylis NB, Ritter A, Kelly SA, et al. Reduced cell surface levels of C-C chemokine receptor 5 and immunosuppression in long coronavirus disease 2019 syndrome [published online ahead of print, 2022 Apr 22]. Clin Infect Dis 2022:ciac226. - PMC - PubMed
    1. Anonymous . Statement on Leronlimab. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab. 17 May 2021. Accessed 24 April 2022.
    1. Haffer AST. WARNING LETTER CytoDyn, Inc. MARCS-CMS 626957—FEBRUARY 11, 2022. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-inve.... Accessed 24 April 2022.
    1. Galanti M, Shaman J. Direct observation of repeated infections with endemic coronaviruses. J Infect Dis 2021; 223:409–15. - PMC - PubMed
    1. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96:5215–20. - PMC - PubMed